AUS
NZ
UK
CA
USA
IND
Highlights
- OKYO Pharma Ltd begins Phase 2 trial of OK-101 for neuropathic corneal pain (NCP).
- The trial targets a chronic condition currently lacking FDA-approved treatments.
- The study involves a randomized, placebo-controlled format to evaluate safety and efficacy.
OKYO Pharma Ltd (NASDAQ:OKYO), a company operating in the healthcare sector, has initiated its Phase 2 trial for the investigational therapeutic OK-101. The trial is designed to target neuropathic corneal pain (NCP), a condition linked to nerve damage and inflammation affecting the cornea. OKYO Pharma’s efforts aim to explore a solution for this chronic and painful condition, which currently lacks any Food and Drug Administration (FDA)-approved treatments.
Understanding Neuropathic Corneal Pain (NCP)
Neuropathic corneal pain is a condition that affects the cornea, causing discomfort and heightened sensitivity in the eyes, face, or head. It is thought to result from nerve damage accompanied by inflammation, leading to significant and often chronic discomfort for those affected. At present, treatment options are limited to off-label use of various topical and systemic therapies, highlighting a gap in the market for a specialized, approved solution.
Details of the Phase 2 Trial
The Phase 2 trial initiated by OKYO Pharma represents the first study specifically aimed at addressing NCP with a targeted therapy. The study involves a randomized, placebo-controlled format and will run for a period of 12 weeks. The trial will include a total of 48 patients and is being led by an expert in ocular pain, who is also one of the co-inventors of OK-101. The trial’s objective is to rigorously assess the safety and effectiveness of OK-101 in mitigating the symptoms of NCP.
Significance of OK-101 in the Treatment Landscape
OKYO Pharma’s OK-101 is positioned as a potential breakthrough therapy for NCP. The absence of FDA-approved treatments for this condition underscores the importance of this trial. By focusing on the development of a dedicated therapeutic option, OKYO Pharma aims to provide a novel solution that could address the unmet needs of patients suffering from this chronic ocular condition.
Moving Forward with the Development
As the trial progresses, OKYO Pharma remains committed to advancing the research and enrollment process. The company aims to evaluate OK-101 rigorously, ensuring that the study meets the standards required for assessing its safety and therapeutic potential. The trial’s success could pave the way for a significant advancement in the treatment options available to individuals living with NCP.
